Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The New York Times The New York Times

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.

Read full article at The New York Times →